Latest Industry Insights

Shark-derived squalene is a common adjuvant product found in several approved vaccines. As calls for a sustainable source of squalene increase, researchers are exploring how yeast can be used to produce squalene analogues.

In this interview, Technology Networks spoke to Dr. Stuart Marcus, founder and chief medical officer of SonALAsense, to find out how ALA sonodynamic therapy could be a more effective treatment for diffuse intrinsic pontine glioma and recurrent glioblastoma.

This article will cover innovations in structural proteomics, a new way to identify drug targets across the proteome, a new method to dissect drug–protein interactions and the future of structure-based drug design.

Technology Networks spoke to Katherine Tran from SCIEX about the latest advances in data-independent acquisition mass spectrometry and how it can be used to further our understanding of the proteome in health and disease.

Through automating processes and workflows, scientists can optimize their time and concentrate on high-value tasks. At SLAS 2023, Technology Networks interviewed Lars Kristiansen, general manager of Agilent’s Automation Solutions Business. We discussed Agilent’s automation portfolio that was showcased at the event, in addition to trends and challenges in automation.

Automated liquid handling methods are an attractive alternative to manual approaches, allowing labs to redirect important resources. At SLAS 2023, Technology Networks spoke with Thermo Fisher Scientific to discuss how automated liquid dispensing can support versatility in biotech.

To find out more about the importance of improving biomarker discovery and how next-generation mass spectrometry-based systems can help to fill the current gap in biomarker technologies, Technology Networks spoke with Dr. Mo Jain.

In this opinion piece, Liz Sparrow discusses the real risk of the UK losing its science and technology communities as they face a series of challenges that are threatening their growth.

Dr. Adam Crowe sheds light on why a newly discovered reactive impurity is detrimental to mRNA function and how it can be detected more accurately.

To find out more about how generative artificial intelligence (AI) is helping to accelerate and advance drug discovery processes, we spoke to Dr. Alex Zhavoronkov, CEO of Insilico Medicine.